The Claim
In female mice subjected to transverse aortic constriction, treatment with the anti-myostatin antibody mRK35 for 8 weeks increased gastrocnemius muscle fiber cross-sectional area by approximately 15% and forelimb grip strength by 19%, without altering left ventricular wall thickness or cardiomyocyte size.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In female mice with a surgically induced heart condition, an antibody treatment targeting myostatin for eight weeks increased leg muscle size and grip strength without changing heart muscle structure.
See the scientific wording
In female mice subjected to transverse aortic constriction, treatment with the anti-myostatin antibody mRK35 for 8 weeks increased gastrocnemius muscle fiber cross-sectional area by approximately 15% (from 1,105 to 1,266 µm²) and forelimb grip strength by 19% (from 0.86 to 1.02 N), without altering left ventricular wall thickness or cardiomyocyte size, demonstrating a dissociation between skeletal muscle hypertrophy and cardiac remodeling.
Blocking myostatin allows muscle cells to build more protein, making muscle fibers thicker and stronger, which improves grip strength, without affecting the heart's size or structure.
What the research says
1 studyStudy: Evaluating the effects of mRK35 by targeting myostatin in the pressure-overloaded heart.
In mice with a strained heart, a drug that blocks myostatin made their leg muscles bigger and stronger, but didn’t fix or worsen the heart’s enlargement — so it helps muscles without hurting or helping the heart.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.